Bydureon reduces cardiovascular risk factors in Type 2 Diabetes patients

Patients receiving Bydureon (exenatide extended release), a drug for Type 2 Diabetes from Amylin, Eli Lilly and Alkermes experienced significant improvements in specific cardiovascular risk factors compared to patients who received more commonly prescribed treatments. The results show that patients receiving Bydureon experienced improvements related to body weight, abnormal blood pressure and abnormal lipid levels. The analysis from the DURATION-3 trial demonstrated statistically significant reduction in body weight of 9.8 pounds compared to conventional treatment. The analysis of the DURATION-4 trial reveals the patients reached a composite endpoint of A1C <7 percent plus target systolic blood pressure (><130 mmhg) and target ldl cholesterol (><100 mg dl) (16 percent for bydureon vs. 10 percent for actos, 7 percent for januvia and 13 percent for metformin. these findings will be presented at the 47th european association for the study of diabetes annual meeting 2011.>